Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications.
Mateusz KciukManzar AlamNemat AliSummya RashidPola GłowackaRajamanikandan Sundarajİsmail ÇelikEsam Bashir YahyaAmit DubeyEnfale ZerrougRenata KontekPublished in: Molecules (Basel, Switzerland) (2023)
Cellular signaling pathways involved in the maintenance of the equilibrium between cell proliferation and apoptosis have emerged as rational targets that can be exploited in the prevention and treatment of cancer. Epigallocatechin-3-gallate (EGCG) is the most abundant phenolic compound found in green tea. It has been shown to regulate multiple crucial cellular signaling pathways, including those mediated by EGFR, JAK-STAT, MAPKs, NF-κB, PI3K-AKT-mTOR, and others. Deregulation of the abovementioned pathways is involved in the pathophysiology of cancer. It has been demonstrated that EGCG may exert anti-proliferative, anti-inflammatory, and apoptosis-inducing effects or induce epigenetic changes. Furthermore, preclinical and clinical studies suggest that EGCG may be used in the treatment of numerous disorders, including cancer. This review aims to summarize the existing knowledge regarding the biological properties of EGCG, especially in the context of cancer treatment and prophylaxis.
Keyphrases
- papillary thyroid
- signaling pathway
- squamous cell
- cell proliferation
- oxidative stress
- healthcare
- small cell lung cancer
- endoplasmic reticulum stress
- dna methylation
- lymph node metastasis
- anti inflammatory
- stem cells
- bone marrow
- young adults
- tyrosine kinase
- mesenchymal stem cells
- inflammatory response
- cell cycle arrest
- induced apoptosis
- replacement therapy